MedTrace Logo

Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section

NCT02279628 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-10-31

No results posted yet for this study

Summary

The cesarean section is considered as a painful surgery during the post operative period. Mothers may need to move immediately after the surgery to take care of their babies. This may increase the risk of major pain and chronic pain. Thus, excellent postoperative analgesia is required so that mothers do not experience pain in caring for their baby. Currently, several techniques have been developed to manage postoperative pain related to c-section scar such as intrathecal morphine during spinal anesthesia or continuous pre-peritoneal wound infiltration. The comparison between anesthetic techniques has never been performed and it is still not know if the combination of intrathecal morphine plus continuous pre-peritoneal wound infiltration provide a synergistic or additional effect on pain relief.

Conditions

  • Postoperative Pain

Interventions

DRUG

Ropivacaine

Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)

DRUG

Morphine

Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period

Sponsors & Collaborators

  • Maternite Regionale Universitaire

    collaborator OTHER

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Hervé BOUAZIZ, MD., PhD. · Department of Anesthesiology, Maternité Régionale Universitaire, CHU NANCY, France

  • Florence VIAL, MD. · Department of Anesthesiology, Maternité Régionale Universitaire, CHU NANCY, France

  • Philippe GUERCI, MD · Department of Anesthesiology and Critical Care Medicine, CHU NANCY Brabois, FRANCE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-12-31
Completion
2017-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02279628 on ClinicalTrials.gov